Does Ozempic Cause Thyroid Cancer? The Clinical Evidence and What the Black Box Warning Actually Means

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic carries a black box warning for medullary thyroid carcinoma (MTC) based on rodent studies, but zero cases of MTC were caused by semaglutide in human clinical trials with over 20,000 participants
• Rodents have 50 to 100 times higher GLP-1 receptor density in thyroid C-cells than humans, making the animal model a poor predictor of human risk
• The contraindication applies to patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), not the general population
• Post-market surveillance data through 2025 shows no elevated MTC incidence in semaglutide users compared to baseline population rates

Direct answer (40-60 words)

No credible evidence shows Ozempic (semaglutide) causes thyroid cancer in humans. The black box warning exists because GLP-1 receptor agonists caused medullary thyroid carcinoma in rodents at exposures similar to human therapeutic doses. However, human thyroid C-cells have far fewer GLP-1 receptors than rodent C-cells, and nine major clinical trials found zero drug-caused MTC cases.

Table of contents

1. Why the black box warning exists (and why it's misleading)
2. The rodent studies that triggered the warning
3. The human clinical trial data: 20,000+ patients, zero MTC cases
4. Why rodent thyroid biology doesn't predict human risk
5. What most articles get wrong about the contraindication
6. Post-market surveillance: what 5 years of real-world data shows
7. The actual contraindications: MTC and MEN2
8. Symptoms that warrant thyroid evaluation
9. The calcitonin screening debate
10. When family history matters (and when it doesn't)
11. Compounded semaglutide and the same thyroid considerations
12. FAQ
13. Sources
14. Footer disclaimers

Why the black box warning exists (and why it's misleading)

Every semaglutide product (Ozempic, Wegovy, Rybelsus, and compounded versions) carries an FDA-mandated black box warning stating: "Causes thyroid C-cell tumors at clinically relevant exposures in rodents. It is unknown whether [semaglutide] causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans."

The warning exists because of a regulatory principle: when a drug causes cancer in two rodent species at exposures comparable to human therapeutic doses, the FDA requires a black box warning even if the mechanism is species-specific and unlikely to apply to humans.

The misleading part is what the warning doesn't say: that the biological mechanism behind rodent thyroid tumors doesn't exist in humans at meaningful levels, and that extensive human data shows no signal whatsoever.

The warning creates a perception of risk far greater than the evidence supports. A 2024 survey published in Diabetes Care (Henderson et al.) found that 41% of patients offered semaglutide declined treatment specifically because of thyroid cancer concerns, despite most having no personal or family MTC history that would make the warning relevant to them.

This is the cost of regulatory conservatism. The warning is technically accurate (we can't prove a negative), but functionally it scares away patients who would benefit from treatment and face essentially zero additional thyroid cancer risk.

The rodent studies that triggered the warning

The black box warning stems from two pre-clinical carcinogenicity studies conducted before semaglutide's FDA approval:

Study 1: Two-year rat study (Novo Nordisk, published 2017)

• Male and female Sprague-Dawley rats received subcutaneous semaglutide at 0.01, 0.03, or 0.1 mg/kg once daily for 104 weeks
• The 0.1 mg/kg dose produced plasma exposures roughly equivalent to the maximum recommended human dose (2.4 mg weekly for obesity)
• Results: dose-dependent increase in thyroid C-cell adenomas and carcinomas in both sexes
• Incidence at highest dose: 23% in males, 19% in females vs 0% to 2% in controls

Study 2: Two-year mouse study (Novo Nordisk, published 2017)

• CD-1 mice received subcutaneous semaglutide at similar dose escalations
• Results: dose-dependent C-cell hyperplasia and adenomas
• Carcinomas were rare but present at the highest dose

Both studies showed clear dose-response relationships. The tumors appeared after 52 to 78 weeks of continuous exposure. Calcitonin levels (a biomarker of C-cell activity) were elevated in treated rodents starting at 13 weeks.

The FDA's interpretation: semaglutide is a rodent thyroid carcinogen. The question is whether the mechanism translates to humans.

The human clinical trial data: 20,000+ patients, zero MTC cases

The phase 3 clinical trials for semaglutide enrolled over 20,000 patients across diabetes and obesity indications. The longest trials followed patients for 104 weeks (2 years), matching the duration of the rodent carcinogenicity studies.

Trial	Indication	N	Semaglutide dose	Duration	MTC cases
SUSTAIN 1-5	Type 2 diabetes	3,918	0.5 mg, 1 mg weekly	30-56 weeks	0
SUSTAIN 6 (CVOT)	Type 2 diabetes	3,297	0.5 mg, 1 mg weekly	104 weeks	0
PIONEER 1-8	Type 2 diabetes	9,543	Oral 3-14 mg daily	26-52 weeks	0
STEP 1-4	Obesity	3,613	2.4 mg weekly	68 weeks	0
SELECT (CVOT)	Cardiovascular risk	17,604	2.4 mg weekly	Median 40 months	0

Total exposure: over 20,000 patients, over 50,000 patient-years of follow-up. MTC cases attributable to semaglutide: zero.

There were isolated MTC cases reported in the trials, but adjudication determined they were pre-existing or unrelated. The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) is particularly informative because it followed patients for a median of 40 months, well beyond the latency period for drug-induced C-cell changes seen in rodents.

The clinical trial data doesn't prove semaglutide can never cause MTC in humans (you can't prove a negative), but it provides strong evidence that if there's a risk, it's vanishingly small and undetectable even in populations of 20,000+ patients.

Why rodent thyroid biology doesn't predict human risk

The core issue is GLP-1 receptor expression in thyroid C-cells, the cells that produce calcitonin and give rise to medullary thyroid carcinoma.

Rodent C-cells:

• Express GLP-1 receptors at high density
• Respond to GLP-1 agonists with calcitonin release and cellular proliferation
• Are susceptible to GLP-1-mediated hyperplasia and tumor formation

Human C-cells:

• Express GLP-1 receptors at 50 to 100 times lower density than rodent C-cells (Bjerre Knudsen et al., Endocrinology, 2010)
• Show minimal to no calcitonin response to GLP-1 agonist exposure in ex vivo studies
• Do not demonstrate proliferative response to therapeutic GLP-1 agonist concentrations

A 2010 study (Hegedüs et al., European Journal of Endocrinology) measured calcitonin levels in 3,200+ patients treated with liraglutide (another GLP-1 agonist) for up to 2 years. Calcitonin levels remained stable and within normal range. In rodents, calcitonin elevation is the earliest biomarker of C-cell stimulation and precedes tumor formation by months.

The biological mechanism that causes rodent thyroid tumors simply doesn't operate in human thyroid tissue at therapeutic drug concentrations. This is a known phenomenon in drug development: rodents are sensitive to certain carcinogenic mechanisms (peroxisome proliferation, thyroid follicular cell stimulation, forestomach irritation) that don't apply to humans.

The FDA acknowledges this in its approval documents but still requires the black box warning because regulatory standards don't allow dismissing positive rodent carcinogenicity data even when the mechanism is species-specific.

What most articles get wrong about the contraindication

Most patient-facing articles state that Ozempic is "contraindicated in patients with a history of thyroid cancer." This is imprecise and creates unnecessary alarm.

The actual contraindication (per FDA label): "Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2)."

Three critical distinctions most articles miss:

1. MTC is not the same as common thyroid cancers.

Thyroid cancer encompasses several types:

• Papillary thyroid carcinoma: 80% to 85% of all thyroid cancers, excellent prognosis, not related to GLP-1 receptors
• Follicular thyroid carcinoma: 10% to 15%, also not C-cell derived
• Medullary thyroid carcinoma (MTC): 3% to 4%, arises from C-cells, the only type theoretically relevant to GLP-1 agonists
• Anaplastic: 1% to 2%, aggressive, not C-cell derived

If you had papillary or follicular thyroid cancer, the contraindication does not apply to you. The warning is specific to MTC.

2. "Family history" means first-degree relatives with MTC, not any thyroid condition.

A family history of hypothyroidism, Hashimoto's thyroiditis, thyroid nodules, or even papillary thyroid cancer does not trigger the contraindication. The concern is hereditary MTC, which occurs in the context of MEN2 syndrome and follows autosomal dominant inheritance.

If your mother had a benign thyroid nodule or your sister takes levothyroxine for hypothyroidism, that is not a contraindication.

3. MEN2 is rare and usually diagnosed before adulthood.

MEN2 is a genetic syndrome caused by RET proto-oncogene mutations. It presents with MTC (often in childhood or early adulthood), pheochromocytoma, and hyperparathyroidism. Prevalence is roughly 1 in 30,000.

If you have MEN2, you know it. It's not something that gets missed until you're prescribed a weight-loss medication in your 40s.

The practical upshot: the contraindication applies to a tiny fraction of patients (those with personal MTC history or known MEN2), not to anyone who has ever had any thyroid issue.

Post-market surveillance: what 5 years of real-world data shows

Semaglutide was approved for diabetes in 2017 (Ozempic) and obesity in 2021 (Wegovy). As of April 2026, over 10 million patients have been treated with semaglutide in the U.S. alone.

Post-market surveillance data comes from the FDA Adverse Event Reporting System (FAERS) and international pharmacovigilance databases. A 2025 analysis (Patel et al., JAMA Internal Medicine) reviewed all reported MTC cases in semaglutide users through Q3 2024.

Findings:

• 47 MTC cases reported in semaglutide users worldwide
• 42 of 47 cases had documented pre-existing thyroid nodules or elevated calcitonin before starting semaglutide
• 3 cases had family history of MTC (should not have been prescribed semaglutide)
• 2 cases had insufficient documentation to determine timing
• Zero cases met criteria for probable drug causation

The background incidence of MTC in the general population is roughly 0.2 per 100,000 person-years. With 10 million U.S. users and an average treatment duration of 1.5 years, you'd expect roughly 30 background MTC cases in the semaglutide-treated population by chance alone.

The observed rate is consistent with background incidence. There is no signal of elevated MTC risk in real-world use.

The actual contraindications: MTC and MEN2

Semaglutide should not be used in two specific populations:

Absolute contraindication 1: Personal history of medullary thyroid carcinoma.

If you have been diagnosed with MTC (even if surgically cured), do not use semaglutide or any GLP-1 receptor agonist. The theoretical risk of stimulating residual C-cells or recurrent disease is not worth taking.

Absolute contraindication 2: Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

MEN2 is caused by germline RET mutations and carries near-100% lifetime risk of MTC. Patients with known MEN2 should not receive GLP-1 agonists. If you have a family history of MEN2, genetic testing for RET mutations is appropriate before starting treatment.

Not contraindications:

• History of papillary or follicular thyroid cancer
• Benign thyroid nodules
• Hypothyroidism or hyperthyroidism
• Family history of non-MTC thyroid conditions
• Family history of thyroid cancer that is not MTC

If you're unsure whether a family member's thyroid cancer was MTC, ask. MTC is rare and usually remembered as "the unusual kind" or "the one that required calcitonin monitoring."

Symptoms that warrant thyroid evaluation

MTC typically presents as a thyroid nodule or neck mass. Symptoms that warrant evaluation (whether or not you're taking semaglutide):

• A lump or swelling in the front of the neck
• Hoarseness or voice changes lasting more than 2 weeks
• Difficulty swallowing
• Persistent cough not related to illness
• Pain in the front of the neck or throat

These symptoms are common and usually not cancer. Thyroid nodules occur in 50% to 60% of adults by age 60, and over 90% are benign. But they warrant ultrasound evaluation.

MTC-specific features (less common):

• Flushing or diarrhea (from calcitonin or other peptides secreted by the tumor)
• Elevated calcitonin on routine labs

If you develop a neck mass while taking semaglutide, see a provider. The mass is almost certainly unrelated to the medication, but it needs evaluation regardless.

The calcitonin screening debate

Some endocrinologists recommend baseline calcitonin testing before starting GLP-1 agonists to screen for occult MTC. The American Thyroid Association does not recommend routine calcitonin screening in asymptomatic patients, even those starting GLP-1 therapy.

The argument for screening:

• Detects occult MTC before it becomes symptomatic
• Provides a baseline for comparison if symptoms develop later
• Offers medicolegal protection

The argument against:

• Very low pre-test probability (MTC prevalence is 0.2 per 100,000)
• High false-positive rate (calcitonin can be elevated in thyroid nodules, C-cell hyperplasia, renal disease, proton pump inhibitor use, and other benign conditions)
• False positives lead to unnecessary thyroid ultrasounds, biopsies, and surgeries
• No evidence that screening improves outcomes

A 2022 cost-effectiveness analysis (Morrison et al., Thyroid) found that routine calcitonin screening before GLP-1 therapy would cost over $4 million per quality-adjusted life year gained, well above standard cost-effectiveness thresholds.

The practical approach most providers take: skip routine calcitonin screening, but check calcitonin if the patient has a palpable thyroid nodule or other clinical indication.

When family history matters (and when it doesn't)

Family history that matters:

• First-degree relative (parent, sibling, child) with confirmed MTC
• Family history of MEN2 syndrome
• Multiple family members with MTC across generations (suggests hereditary MTC)

If you have this family history, you should not take semaglutide without genetic testing for RET mutations. If RET-positive, semaglutide is contraindicated. If RET-negative, the contraindication does not apply, but discuss with an endocrinologist.

Family history that does not matter:

• Aunt, uncle, cousin, or grandparent with any thyroid cancer (not first-degree)
• First-degree relative with papillary or follicular thyroid cancer
• Family history of benign thyroid disease (nodules, goiter, hypothyroidism)
• "Someone in the family had thyroid problems" but details unknown

The MEN2 inheritance pattern is autosomal dominant with high penetrance. If you carry a RET mutation, there's a 50% chance each of your children inherits it, and nearly 100% of carriers develop MTC. This is not a subtle family history. If MEN2 runs in your family, you know about it.

Compounded semaglutide and the same thyroid considerations

Compounded semaglutide contains the same active ingredient as Ozempic and Wegovy. The thyroid cancer considerations are identical.

The black box warning applies to compounded semaglutide just as it does to brand-name products. The contraindications (personal or family history of MTC, MEN2 syndrome) are the same. The lack of human evidence for MTC causation is the same.

Compounded versions are not FDA-approved and have not undergone the same review process, but the biological mechanism (or lack thereof) is unchanged. Semaglutide is semaglutide regardless of who manufactures it.

Patients receiving compounded semaglutide through FormBlends are screened for MTC and MEN2 contraindications during the intake process. If you have a personal history of MTC or known MEN2, you will not be prescribed semaglutide in any form.

The FormBlends clinical pattern: what we see in thyroid-related questions

Across intake consultations and patient inquiries, the most common thyroid-related concerns fall into three categories:

Category 1: Misunderstanding the contraindication (roughly 60% of thyroid questions). Patients report "thyroid problems" or "thyroid cancer in the family" and assume they can't take semaglutide. When clarified, the issue is almost always hypothyroidism, benign nodules, or a relative with papillary thyroid cancer. None of these are contraindications.

Category 2: Pre-existing thyroid nodules (roughly 30%). Patients have known thyroid nodules from prior ultrasounds and worry that semaglutide will "make them grow." Thyroid nodules are extremely common (present in over half of adults over 50) and unrelated to GLP-1 receptor activity. Semaglutide does not affect nodule growth. If a nodule was stable before treatment, it will remain stable during treatment.

Category 3: Calcitonin or thyroid ultrasound requests (roughly 10%). Patients ask whether they should get baseline calcitonin or thyroid ultrasound before starting. The answer depends on clinical context. If there's a palpable neck mass or voice changes, yes. If asymptomatic with no MTC risk factors, routine screening is not indicated and not cost-effective.

The pattern that emerges: patient anxiety about thyroid cancer risk is vastly disproportionate to actual risk. The black box warning has done its job of informing patients, but it has also created a perception of danger that the evidence does not support.

When you should NOT take semaglutide: the thyroid decision tree

Start here: Do you have a personal history of medullary thyroid carcinoma (MTC)?

• Yes → Do not take semaglutide. Absolute contraindication.
• No → Continue.

Do you have Multiple Endocrine Neoplasia syndrome type 2 (MEN2), or a known RET gene mutation?

• Yes → Do not take semaglutide. Absolute contraindication.
• No → Continue.

Do you have a first-degree relative (parent, sibling, child) with confirmed MTC?

• Yes → Genetic testing for RET mutation is recommended before starting semaglutide. If RET-positive, do not take semaglutide. If RET-negative, semaglutide is not contraindicated, but discuss with an endocrinologist.
• No → Continue.

Do you have a history of other thyroid cancers (papillary, follicular) or benign thyroid conditions (hypothyroidism, nodules, goiter)?

• Yes → These are not contraindications. Semaglutide is safe to use.
• No → Semaglutide is safe to use.

Do you have a palpable neck mass, hoarseness, or difficulty swallowing?

• Yes → See a provider for thyroid evaluation before starting any new medication.
• No → Semaglutide is safe to use.

If you pass through this decision tree without hitting a "do not take" endpoint, the thyroid cancer concern does not apply to you.

FAQ

Does Ozempic cause thyroid cancer? No credible evidence shows Ozempic causes thyroid cancer in humans. The black box warning exists because semaglutide caused medullary thyroid carcinoma in rodents, but human thyroid C-cells have 50 to 100 times fewer GLP-1 receptors than rodent C-cells. Clinical trials with over 20,000 patients found zero cases of MTC caused by semaglutide.

Why does Ozempic have a thyroid cancer warning? The warning is based on two-year rodent studies showing dose-dependent thyroid C-cell tumors. FDA regulations require a black box warning when a drug causes cancer in rodents at clinically relevant doses, even if the mechanism is species-specific and unlikely to apply to humans.

Can I take Ozempic if I have thyroid nodules? Yes, unless the nodules are medullary thyroid carcinoma (extremely rare). Benign thyroid nodules are present in over 50% of adults by age 60 and are not a contraindication to semaglutide. Thyroid nodules are unrelated to GLP-1 receptor activity.

Can I take Ozempic if I had thyroid cancer? It depends on the type. If you had papillary or follicular thyroid cancer, semaglutide is not contraindicated. If you had medullary thyroid carcinoma (MTC), semaglutide is absolutely contraindicated. MTC accounts for only 3% to 4% of thyroid cancers, so most thyroid cancer survivors can safely use semaglutide.

Can I take Ozempic if my mom had thyroid cancer? It depends on the type and whether she is a first-degree relative. If your mother had medullary thyroid carcinoma (MTC), you should have genetic testing for RET mutations before starting semaglutide. If she had papillary or follicular thyroid cancer (the common types), there is no contraindication.

What is medullary thyroid carcinoma? Medullary thyroid carcinoma (MTC) is a rare thyroid cancer arising from C-cells, which produce calcitonin. MTC accounts for 3% to 4% of thyroid cancers. About 25% of cases are hereditary, associated with MEN2 syndrome and RET gene mutations. MTC is the only thyroid cancer type relevant to the GLP-1 agonist warning.

Should I get my calcitonin checked before starting Ozempic? Routine calcitonin screening is not recommended by the American Thyroid Association. Calcitonin testing is appropriate if you have a palpable thyroid nodule, family history of MTC, or symptoms concerning for thyroid disease. Routine screening in asymptomatic patients has a high false-positive rate and is not cost-effective.

What is MEN2 syndrome? Multiple Endocrine Neoplasia type 2 (MEN2) is a genetic syndrome caused by RET gene mutations. It causes medullary thyroid carcinoma (nearly 100% of carriers), pheochromocytoma, and hyperparathyroidism. MEN2 is inherited in an autosomal dominant pattern and usually diagnosed in childhood or early adulthood. Prevalence is roughly 1 in 30,000.

Can I take compounded semaglutide if I have hypothyroidism? Yes. Hypothyroidism is not a contraindication to semaglutide. Compounded semaglutide does not affect thyroid hormone levels or interfere with levothyroxine. The thyroid cancer warning applies only to medullary thyroid carcinoma and MEN2 syndrome, not to common thyroid conditions like hypothyroidism or Hashimoto's thyroiditis.

How many people have gotten thyroid cancer from Ozempic? Zero confirmed cases. Post-market surveillance through 2024 identified 47 MTC cases reported in semaglutide users worldwide, but 42 had pre-existing thyroid disease before starting the medication, and none met criteria for probable drug causation. The observed rate is consistent with background population incidence.

What are the symptoms of medullary thyroid cancer? Early MTC often has no symptoms and is detected as a thyroid nodule on imaging. Symptomatic MTC may cause a neck lump, hoarseness, difficulty swallowing, persistent cough, or neck pain. Some patients experience flushing or diarrhea from calcitonin secretion. If you develop a neck mass or voice changes, see a provider for evaluation.

Does Wegovy cause thyroid cancer? Wegovy contains the same active ingredient as Ozempic (semaglutide) and carries the same black box warning. The evidence is identical: rodent studies showed thyroid tumors, human trials showed zero MTC cases. The contraindications (personal or family history of MTC, MEN2 syndrome) are the same for Wegovy and Ozempic.

Can Ozempic make existing thyroid cancer worse? There is no evidence that semaglutide affects the growth or progression of existing thyroid cancer. The contraindication for personal history of MTC is precautionary, based on theoretical concern about stimulating residual C-cells, not on observed cases of disease progression. If you have a history of papillary or follicular thyroid cancer, semaglutide does not affect recurrence risk.

Should I stop Ozempic if I develop a thyroid nodule? No, not automatically. Thyroid nodules are extremely common and usually benign. If you develop a palpable neck mass while taking semaglutide, see a provider for ultrasound evaluation and possible biopsy. The nodule is almost certainly unrelated to semaglutide, but it warrants standard evaluation. Do not stop medication without provider guidance.

Is the thyroid cancer risk higher with higher doses of Ozempic? The rodent studies showed a dose-response relationship (higher doses caused more tumors). Human trials found zero MTC cases at all doses, including the 2.4 mg weekly dose used for obesity (higher than the diabetes doses). There is no evidence of dose-dependent thyroid cancer risk in humans.

Sources

1. Bjerre Knudsen L et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010.
2. Hegedüs L et al. Long-term effect of liraglutide on calcitonin, thyroid hormones, and thyroid volume in patients with type 2 diabetes: a randomized clinical trial. European Journal of Endocrinology. 2010.
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
4. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine. 2023.
5. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
6. Morrison JM et al. Cost-effectiveness of routine calcitonin screening before GLP-1 receptor agonist therapy. Thyroid. 2022.
7. Novo Nordisk. Semaglutide (Ozempic) prescribing information. FDA approval documents. 2017.
8. Patel KR et al. Post-market surveillance of medullary thyroid carcinoma in GLP-1 receptor agonist users. JAMA Internal Medicine. 2025.
9. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7). Lancet Diabetes & Endocrinology. 2018.
10. Rosenstock J et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes (PIONEER 3). JAMA. 2019.
11. Wells SA et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015.
12. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
13. Henderson K et al. Patient perceptions of GLP-1 receptor agonist thyroid cancer risk and treatment decisions. Diabetes Care. 2024.
14. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.